^
    Back
    Association details:
    Biomarker:CCL5 overexpression
    Cancer:Glioblastoma
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cell Res
    Title:

    Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

    Published date:
    07/08/2021
    Excerpt:
    GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC.
    Secondary therapy:
    temozolomide
    DOI:
    10.1038/s41422-021-00528-3